1188 related articles for article (PubMed ID: 12576334)
1. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
2. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R
Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592
[TBL] [Abstract][Full Text] [Related]
3. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
Jiang G; Yang F; Li M; Weissbecker K; Price S; Kim KC; La Russa VF; Safah H; Ehrlich M
Cancer Biol Ther; 2003; 2(1):103-8. PubMed ID: 12673129
[TBL] [Abstract][Full Text] [Related]
4. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
Song YP; Fang BJ; Wei XD; Zheng S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
[TBL] [Abstract][Full Text] [Related]
5. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.
Holtz MS; Slovak ML; Zhang F; Sawyers CL; Forman SJ; Bhatia R
Blood; 2002 May; 99(10):3792-800. PubMed ID: 11986238
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
Bashir Q; De Lima MJ; McMannis JD; Garcia-Manero G; Shpall E; Kantarjian H; Cortes JE; O'Brien SM; Jones D; Qazilbash M; Wei W; Giralt SA; Champlin RE; Hosing C
Leuk Lymphoma; 2010 Aug; 51(8):1478-84. PubMed ID: 20658954
[TBL] [Abstract][Full Text] [Related]
8. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Chu S; Holtz M; Gupta M; Bhatia R
Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
[TBL] [Abstract][Full Text] [Related]
9. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
10. Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.
Holtz MS; Bhatia R
Leuk Lymphoma; 2004 Feb; 45(2):237-45. PubMed ID: 15101707
[TBL] [Abstract][Full Text] [Related]
11. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Sawyers CL
Semin Hematol; 2001 Jul; 38(3 Suppl 8):15-21. PubMed ID: 11526597
[TBL] [Abstract][Full Text] [Related]
12. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
Chu S; McDonald T; Lin A; Chakraborty S; Huang Q; Snyder DS; Bhatia R
Blood; 2011 Nov; 118(20):5565-72. PubMed ID: 21931114
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
Press RD; Love Z; Tronnes AA; Yang R; Tran T; Mongoue-Tchokote S; Mori M; Mauro MJ; Deininger MW; Druker BJ
Blood; 2006 Jun; 107(11):4250-6. PubMed ID: 16467199
[TBL] [Abstract][Full Text] [Related]
14. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
Konig H; Holyoake TL; Bhatia R
Blood; 2008 Feb; 111(4):2329-38. PubMed ID: 18056843
[TBL] [Abstract][Full Text] [Related]
15. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
Topaly J; Zeller WJ; Fruehauf S
Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
[TBL] [Abstract][Full Text] [Related]
16. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
[TBL] [Abstract][Full Text] [Related]
17. Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction.
Stentoft J; Pallisgaard N; Kjeldsen E; Holm MS; Nielsen JL; Hokland P
Eur J Haematol; 2001; 67(5-6):302-8. PubMed ID: 11872078
[TBL] [Abstract][Full Text] [Related]
18. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
19. Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.
Thiele J; Kvasnicka HM; Varus E; Ollig E; Schmitt-Graeff A; Staib P; Griesshammer M
Leuk Lymphoma; 2004 Aug; 45(8):1627-31. PubMed ID: 15370216
[TBL] [Abstract][Full Text] [Related]
20. Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.
Abe A; Minami Y; Hayakawa F; Kitamura K; Nomura Y; Murata M; Katsumi A; Kiyoi H; Jamieson CHM; Wang JYJ; Naoe T
Int J Hematol; 2008 Dec; 88(5):471-475. PubMed ID: 19039626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]